Skip to main content
Noreen Henig, MD, Pulmonology, San Francisco, CA

NoreenRothHenigMD

Pulmonology San Francisco, CA

Critical Care Medicine

Sr. Director, Cardiopulmonary Medical Affairs

Dr. Henig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Henig's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1998
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 1992 - 1995
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1994 - 2026

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in ...
    Noreen Roth Henig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
    Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 1st, 2023
  • Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
    Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisJune 27th, 2022
  • Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
    Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisNovember 15th, 2021
  • Join now to see all